Search

1244447
1240861
1230819
1195994
393884
Final results from M72 AS01E TB Vaccine Trial
The final results from the M72AS01E TB vaccine study have been published in the New England Journal of Medicine. The vaccine demonstrated a 50% efficacy rate in the incidence of lung TB disease in HIV-negative adults, already infected with latent...
Beat TB drama production
Beat TB, a Welcome Trust funded street theater production which raised awareness about tuberculosis (TB) and vaccine research understanding amongst the broader public of the Worcester area. during 2016.
2018 Tb under the Spotlight Science Engagement
The “TB Under the Spotlight Science Engagement” programme was conceptualised and presented by South African Tuberculosis Vaccine Initiative (SATVI) with scientists from the Division of Molecular Biology and Human Genetics at Stellenbosch University...
New multi-functional TB blood test validated
Researchers the South African Tuberculosis Vaccine Initiative (SATVI), the Center for Global Infectious Disease Research(USA) and a large consortium of collaborators have developed a validated a new, simple blood-based test that has the potential to...
Community Engagement
Carina's Choice: SATVI collaborated with UCT Drama Department and Worcester Secondary School in developing this play which was performed by learners from Worcester Secondary School at 8 local high schools reaching approximately 8 000 adolescents in...

News

Wednesday, 14 April 2021
14 April 2021 2021 A blood test to find those at high risk of tuberculosis in people living with HIV.

The Lancet Global Health journal reports the findings of a study of a host blood test that can find those at high risk of tuberculosis in people living with HIV. The blood mRNA biomarker differentiated between people living with HIV who had active tuberculosis from those without TB, and predicted which individuals would develop TB within 15 months.

Publication Date:
Wed, 14 Apr 2021 - 08:00
26 March 2021 In-depth: SA at cutting edge of TB vaccine research

Today, on the 26 March 2001 the 1st participant in the first SATVI BCG- randomised clinical trial was enrolled. Adele Baleta writes in the Daily Maverick about the work that the South African Tuberculosis Vaccine Initiative has been doing the past 20 years in fighting TB. 

Publication Date:
Fri, 26 Mar 2021 - 19:30
26 March 2021 Celebrating 20 years of TB research

On Friday 26 March 2021, SATVI will celebrate its 20th birthday to mark the enrolment in 2001 of the first participant in the first SATVI TB vaccine trial a randomised controlled trial of intradermal vs percutaneous BCG vaccination, Hawkridge BMJ 2008.

Publication Date:
Thu, 25 Mar 2021 - 22:45
21 March 2021 TB vaccine moves into phase II study in people living with HIV.

Cape Town:  Researchers at the South African Tuberculosis Vaccine Initiative (SATVI) research site in Worcester have started recruitment for a phase II vaccine trial to see  if the M72/AS01E TB vaccine is safe and immunogenic in people living with HIV. 

Publication Date:
Tue, 23 Mar 2021 - 16:00

Pages